CX3CL1 and peeling skin syndrome: Furthermore, treatment with rituximab was found to prevent the reduction of NKp30 expression on NK cells, thus diminishing B cells, FDC networks, and ectopic germinal centers.182 In a separate evaluation focusing on the serum levels of CX3CL1 in primary Sjögren’s syndrome (pSS) patients, a significant elevation compared to controls was observed, indicating an inflammatory response.